Human Biotech Animal Health 2019
Human Biotech Animal Health 2019
9 April, 2019
Hyatt Regency Boston Harbor, Boston, MA

Innovating veterinary health with human biotechnology

Photo Gallery

Photos from April 2019 are now available to download and share - view the full photo gallery here.

Human Biotech & Animal Health photos

Series Highlights

   

Attendees at Boston 2018

Who attended Human Biotech & Animal Health

Why Attend

Join the 2nd Annual conference connecting human biotechs with the animal health industry.

Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.

Benefits of the Animal Health industry to Biotechs:

1st
Conference series of its kind
120+
Attendees
11+
1-to-1 Meetings per person
5+
hours of networking

Testimonials

"This was an excellent event. As a newbie to animal health this was an eye opener. Some great connections and introductions. I would highly recommend your conference. The right balance of networking and information. Thank you!"

Sean Ekins, CEO, COLLABORATIONS PHARMA

 

"This conference provided relevant information and has led to a potential collaboration. I thought the conference was well focused. It was time well spent. I learned a lot and had productive networking sessions. The concept of the confluence of Human Biomedical development and Animal health is integral to our business plan. Kalos looks to leverage its proof of concept work as well as safety and tox to create parallel product lines."

George Colberg, CEO, Kalos Therapeutics, Inc.

 

"A well organized conference that established a strong link between biotechnology innovation and potential veterinary uses.”

Michael G. Palfreyman, Director, R&D Advisory Board, PAFOS PHARMA LLC

WHO SHOULD ATTEND?

HUMAN BIOTECHNOLOGY

Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:

 

ANIMAL HEALTH

-  Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies
-  Market Intelligence and Consultancy Providers

 

INVESTMENT & SERVICE PROVIDERS

-  Private Equity & Venture Capital Investors
-  Investment Bankers & M&A advisors
-  Legal Advisory

Benefits of Attending

FORGE RELATIONSHIPS with animal health executives and human biotechs in prescheduled 1-on-1 meetings, and discuss research collaborations, deallicensing and other business development opportunities

Address unmet and underserved medical needs across human and veterinary health

Human Biotechs

Identify the target disease areas in animal health that your human health assets can serve

Explore opportunities for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships

Learn about the different types of partnerships with animal health, such as research collaborations and out-licensing deals - and how these deals work

Animal Health

Form Partnerships with human health innovators to build your R&D and innovation pipeline.

Identify exciting new technologies in human health that may have translational potential for veterinary medicine - they might be the next blockbuster animal health products!

Hear what past attendees had to say:

Speakers

 

Scott Brown

Independent Animal Health Expert

Scott Brown

Independent Animal Health Expert

Scott Brown

Independent Animal Health Expert
 

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis.

Ailis Tweed-Kent

CEO
Cocoon Biotech

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as PEPFAR/Office of U.S. Global AIDS Coordinator, London School of Hygiene & Tropical Medicine, and the Global Health Delivery Project. She brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame.

 

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry.

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses.  He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs.  Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.

 

Lewis Gruber

CEO
SIWA Therapeutics, Inc.

Lewis Gruber is Chief Executive Officer and a founder of SIWA Therapeutics, Inc. (“SIWA”). SIWA is a pre-clinical stage biopharmaceutical company with a first-in-class humanized monoclonal antibody (“mAb”) that binds to a SIWA-identified advanced glycation endproduct target antigen on senescent cells (“SCs”) and removes them. SCs accumulate with aging or exposure to stress and have a causative role in age-related dysfunction and degenerative diseases including.

Lewis Gruber

CEO
SIWA Therapeutics, Inc.

Lewis Gruber

CEO
SIWA Therapeutics, Inc.

Lewis Gruber is Chief Executive Officer and a founder of SIWA Therapeutics, Inc. (“SIWA”). SIWA is a pre-clinical stage biopharmaceutical company with a first-in-class humanized monoclonal antibody (“mAb”) that binds to a SIWA-identified advanced glycation endproduct target antigen on senescent cells (“SCs”) and removes them. SCs accumulate with aging or exposure to stress and have a causative role in age-related dysfunction and degenerative diseases including. by way of example, many cancers, and neurodegenerative diseases such as Parkinson’s, ALS, and Alzheimer’s Disease, SIWA has the complete sequence of SIWA 318H, which provides the basis for senescent cell clearance in any mammalian species. Prior to founding SIWA, Mr. Gruber was a founder of Arryx, Inc., and served as its CEO from 2000 through 2005 (acquired by a publicly-held company).  While Mr. Gruber was at Arryx, it received numerous awards including ones for World Economic Forum Technology Pioneer (2005) and Red Herring Top 100 Innovator for 2004.  Prior to Arryx, he was a founder of Hyseq, Inc, a publicly-held genomics company (subsequently merged). He served as Hyseq’s CEO from 1994 through 2000. While CEO, Hyseq completed the largest IPO of a biotechnology company in 1997 (underwritten by Salomon Smith Barney and others) and obtained collaborations for Hyseq totaling over $10 million. The technology was sold to Beijing Genomics Institute. 

 

George Colberg

CEO
Kalos Therapeutics

George Colberg

CEO
Kalos Therapeutics

George Colberg

CEO
Kalos Therapeutics
 

Jed Hubbs

CEO
NeuroCycle Therapeutics

Jed Hubbs

CEO
NeuroCycle Therapeutics

Jed Hubbs

CEO
NeuroCycle Therapeutics
 

Sharon Chase

Veterinary Regulatory Consultant
Schafer Veterinary Consultants

Dr. Sharon Chase is a small animal veterinarian with over a decade of clinical practice experience gained from working in general and emergency hospitals in Massachusetts and Washington, DC. In addition to clinical practice, Dr. Chase served as a reviewer with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for over seven years. She currently works as a regulatory consultant for the veterinary pharmaceutical industry with Schafer Veterinary Consultants, based in Fort Collins, Colorado.

Sharon Chase

Veterinary Regulatory Consultant
Schafer Veterinary Consultants

Sharon Chase

Veterinary Regulatory Consultant
Schafer Veterinary Consultants

Dr. Sharon Chase is a small animal veterinarian with over a decade of clinical practice experience gained from working in general and emergency hospitals in Massachusetts and Washington, DC. In addition to clinical practice, Dr. Chase served as a reviewer with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for over seven years. She currently works as a regulatory consultant for the veterinary pharmaceutical industry with Schafer Veterinary Consultants, based in Fort Collins, Colorado.

 

Chris Robillard

Director, Business Development
Karyopharm Therapeutics

Chris has spent the last 3 years in business development at Karyopharm helping to advance clinical stage products to commercialization in both the human and animal oncology settings. Karyopharm has tested multiple products in canine oncology, both to inform clinical design in humans and to seek partners to advance products in canine oncology. Chris has spent the over 10 years in pharma/biotech in various business development and financial roles.

Chris Robillard

Director, Business Development
Karyopharm Therapeutics

Chris Robillard

Director, Business Development
Karyopharm Therapeutics

Chris has spent the last 3 years in business development at Karyopharm helping to advance clinical stage products to commercialization in both the human and animal oncology settings. Karyopharm has tested multiple products in canine oncology, both to inform clinical design in humans and to seek partners to advance products in canine oncology. Chris has spent the over 10 years in pharma/biotech in various business development and financial roles.

 

Cheryl London

Oncology Research Professor
Tufts University

Cheryl London

Oncology Research Professor
Tufts University

Cheryl London

Oncology Research Professor
Tufts University
 

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis.

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis. At Eli Lilly/Elanco, she now directs companion animal studies across institutions in order to leverage high quality, systematic translational data with the goal of improving both human and animal health.

 

Erin Wright

Senior Healthcare Technology & Distribution Equity Research Analyst
Analyst

Erin Wright is the senior Healthcare Technology & Distribution Equity Research Analyst at Credit Suisse. Her uniquely broad coverage footprint of 30+ companies spans multiple healthcare sub-sectors including companies in Animal Health, Pharmacy Benefit Management, Pharmaceutical and Medical Distribution, Retail Pharmacy, Dental, Information Technology Services, Clinical Laboratories, and Contract Research Organizations.

Erin Wright

Senior Healthcare Technology & Distribution Equity Research Analyst
Analyst

Erin Wright

Senior Healthcare Technology & Distribution Equity Research Analyst
Analyst

Erin Wright is the senior Healthcare Technology & Distribution Equity Research Analyst at Credit Suisse. Her uniquely broad coverage footprint of 30+ companies spans multiple healthcare sub-sectors including companies in Animal Health, Pharmacy Benefit Management, Pharmaceutical and Medical Distribution, Retail Pharmacy, Dental, Information Technology Services, Clinical Laboratories, and Contract Research Organizations. Erin pioneered a commercial franchise in the Animal Health sector, the first on Wall Street to cover the space in a comprehensive fashion, leveraging her broad experience in equity research covering the pharmaceutical supply chain and products. She has been prominently featured in acclaimed peer reviewed journals as a thought-leader in healthcare industries such as Animal Health. Prior to joining Credit Suisse in 2016, Erin was a lead Equity Research Analyst at Bank of America Merrill Lynch for eight years,  focusing on specific subsectors within healthcare, including Animal Health, Infection Control, and Dental. Erin received a BA in Economics from Harvard University, with an emphasis on Organismic and Evolutionary Biology. She is an avid golfer and lives in New York City.

 

Bruce Taillon

Senior Director, External Innovation
Elanco

Bruce Taillon

Senior Director, External Innovation
Elanco

Bruce Taillon

Senior Director, External Innovation
Elanco
 

Milton Boyle

Business Development
Boehringer Ingelheim Animal Health

Milton has over 30 years experience in animal agriculture and animal health.  He started his career as a commercial poultry geneticist and was head of R&D for 2 primary poultry breeders (Avian Farms International and Hubbard Farms).  Since 2007, he has worked for Merial and now Boehringer Ingelheim as the business development partner for R&D focusing on licenses and research collaborations.

Milton Boyle

Business Development
Boehringer Ingelheim Animal Health

Milton Boyle

Business Development
Boehringer Ingelheim Animal Health

Milton has over 30 years experience in animal agriculture and animal health.  He started his career as a commercial poultry geneticist and was head of R&D for 2 primary poultry breeders (Avian Farms International and Hubbard Farms).  Since 2007, he has worked for Merial and now Boehringer Ingelheim as the business development partner for R&D focusing on licenses and research collaborations.

 

Scott DeWire

Global Head of Business Development for Cancer Immunology
Boehringer Ingelheim

Scott is responsible for immuno-oncology partnerships and licensing at Boehringer Ingelheim Pharmaceuticals Inc.  Scott learned to pipette as an intern and later bench scientist with Pfizer Animal Health in his hometown of Groton, CT.  After Pfizer, he earned a PhD from the University of North Carolina, and completed his postdoc at Duke University with Robert Lefkowitz (2012 Nobel Prize).  Out of his postdoc, Scott co-founded Trevena Inc, a biotech company focused on GPCR biology.  Since joining Boehringer in 2012, Scott has held various roles in the research group before joining BD&L i

Scott DeWire

Global Head of Business Development for Cancer Immunology
Boehringer Ingelheim

Scott DeWire

Global Head of Business Development for Cancer Immunology
Boehringer Ingelheim

Scott is responsible for immuno-oncology partnerships and licensing at Boehringer Ingelheim Pharmaceuticals Inc.  Scott learned to pipette as an intern and later bench scientist with Pfizer Animal Health in his hometown of Groton, CT.  After Pfizer, he earned a PhD from the University of North Carolina, and completed his postdoc at Duke University with Robert Lefkowitz (2012 Nobel Prize).  Out of his postdoc, Scott co-founded Trevena Inc, a biotech company focused on GPCR biology.  Since joining Boehringer in 2012, Scott has held various roles in the research group before joining BD&L in 2016.

Scott has a lifelong love of animals, and he and his family currently have a menagerie of animals that includes his three cherished beagles.

 

David R. Boyko

Director, Global Business Development
Merck Animal Health

David R. Boyko is Director, Global Business Development for Merck Animal Health (known as MSD Animal Health outside the United States and Canada), a part of Merck & Co., Inc., Kenilworth, NJ.  In this role, David is responsible to identify, evaluate, negotiate and execute licensing and business development transactions for animal health products and services, including newly emerging animal diseases, biopharmaceuticals, vaccines, drug and vaccine delivery and new, digital technologies. Geographically, he focuses on opportunities for the North American business units.

David R. Boyko

Director, Global Business Development
Merck Animal Health

David R. Boyko

Director, Global Business Development
Merck Animal Health

David R. Boyko is Director, Global Business Development for Merck Animal Health (known as MSD Animal Health outside the United States and Canada), a part of Merck & Co., Inc., Kenilworth, NJ.  In this role, David is responsible to identify, evaluate, negotiate and execute licensing and business development transactions for animal health products and services, including newly emerging animal diseases, biopharmaceuticals, vaccines, drug and vaccine delivery and new, digital technologies. Geographically, he focuses on opportunities for the North American business units.

Underpinning that role are more than twenty years of legal practice, with twenty of those years as a deal lawyer, business partner and counselor in the life sciences industry. His legal career includes extensive experience in corporate development and licensing activities for prescription, over-the-counter health and animal health products and technologies, as well as in the new area of digital health.  He has advised executive and senior management levels on a broad range of legal issues, including M&A, regulatory, commercial, corporate governance and litigation, managed lawyers and controlled outside counsel annual budgets in excess of $2MM.  David also has been Division Counsel for Healthcare Services & Solutions, Merck's business unit for innovative, non-drug healthcare solutions, a Senior Counsel in the Corporate Transactions Groups of both Merck and Schering-Plough, and an executive officer for Xenogen Corporation.  In private practice, David was with the law firms of Wilson Sonsini Goodrich & Rosati and Fried, Frank, Harris, Shriver & Jacobson.  He has a number of published articles on intellectual property and antitrust matters, and has chaired licensing panels at several annual meetings of the Association of Corporate Counsel.

David earned his J.D. degree from the University of California Los Angeles, his M.A. degree in International Relations from the University of Southern California and his B.S. degree in Mechanical Engineering from Cornell University.  David is also a veteran, having served eight years of active duty as a U.S. Air Force officer.

 

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

Headline Partner

Associate Partners

Event Partners

Media Partner

Agenda

You can download our agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Forge relationships; Identify exciting new technologies; Learn about the different types of patnerships available to you

Headline speakers include:

Download Agenda

Venue

Hyatt Regency Boston Harbor, Boston, MA

Venue: Hyatt Regency Boston Harbor
Address: 101 Harborside Drive, Boston, MA 02128

We have arranged a discounted room rate for all event attendees of $239 per night, exclusive of taxes

To make your reservations, please click here

If you need additional assistance, please contact the hotel Reservation Department on +1 877-803-7534 or click here to find contact information by Region.

Please book by 9th March 2019 - after this rates are subject to availability.

If the group rate is no longer available, prevailing rates may be offered for some or all of your dates.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

Book a Team to Save More!

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Animal Health Investment Europe:

  • Please note that a $79 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Those offering consultancy or market intelligence services do not qualify for the Start-Up rate.
  • PLEASE NOTE – no additional discounts are available on ‘Start-up Company’ pricing. Group discounts are ONLY available on ‘Delegate’ pricing.
  • You can view our Cancellation Policy here.

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.

CONTACT US TO FIND OUT MORE

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

Animal Health USA 2019